

## Pancreatic Head Cancer Developing in the Remnant Pancreas after a Distal Pancreatectomy

**Young-Il Kim, Sang Myung Woo, Woo Jin Lee**

*Department of Internal Medicine and Center for Liver Cancer, National Cancer Center, Korea*

There have been very few reports related to pancreatic cancer recurrence in the remnant pancreas after a partial resection of pancreas. We report a case of pancreatic head cancer developing in the remnant pancreas after a distal pancreatectomy in a 61-year-old man. He visited to the National Cancer Center to evaluate the cause of epigastric pain with 4 weeks duration. He was healthy, non-smoker and non-alcoholics. There were no abnormal laboratory findings, but about 2.3 cm sized low attenuated pancreatic tail mass without vascular invasion and distant metastasis was detected on the abdominal CT scan. He received a distal pancreatectomy and diagnosed as adenosquamous carcinoma. Then, he received adjuvant chemotherapy (gemcitabine 3 cycles) and chemoradiotherapy (capecitabine with conformal radiotherapy). On the follow-up abdomen CT scan, 1.5 cm sized iso-dense mass was detected in the uncinate process of remnant pancreas at 35 months after a distal pancreatectomy. He received a pancreaticoduodenectomy and diagnosed as ductal adenocarcinoma. After the second operation, the patient has remained a state of no evidence of disease for 5 months.

**M/61**

**C/C** Abdominal pain (D: 1 month)

**P/I** 내원 1개월 전 발생한 복통으로 추가 검사 및 치료 위해 내원함

**P/H** DM/ HTN/Hepatitis B/ Pul.TB (-/-/-/-)

**F/H** Not-specific

**S/H** Alcohol (-)/Smoking (-)

**ROS** Anorexia/Nausea/Vomiting (-/-/-)  
Diarrhea/Constipation (-/-)

**P/E** Epigastric T/RT (+/-)

**Lab** CBC:

WBC 6,840/mm<sup>3</sup> Hb 16.1 g/dL Platelet 179,000/mm<sup>3</sup> Chemistry:

Cholesterol 233 mg/dL Protein/ albumin 7.5/4.8 g/dL,

Total bilirubin 0.6 mg/dL

ALP/AST/ALT 106/21/24 U/L

Fasting blood glucose 119 mg/dL

BUN 17 mg/dL, Creatinine 1.3 mg/dL



Pancreatic enzyme:

Amylase 52 U/L, Lipase 43 U/L

Tumor marker:



CA 19-9 114 U/mL (0-37 U/mL)


**2008. 12:**  
**Abdomen CT/PET CT**




### **Hospital course and FU**

- 2009. 01: Surgical treatment  
Distal pancreatectomy + Splenectomy + Lt.adrenalectomy  
(Adenosquamous carcinoma, MD, pT2N1)
- 2009. 02~07: Adjuvant treatment  
Gemcitabine (1,000 mg/m<sup>2</sup>, D1,8,15 q 4 weeks), 2 cycles  
→ Xeloda (1,650 mg Bid, 5 times/week) + RT (50.4 Gy/28Fx)  
→ Gemcitabine (off chemo due to patient's will), 1 cycle
- 2009. 09: Pancreatic DM detection  
Insulin treatment
- 2011. 12: FU Abdomen CT and PET CT  
Uncinate process enhancing lesion in FU-CT, PET (-)
- 2012. 04: FU abdomen CT and PET CT  
Uncinate process lesion increased in CT, PET (+)






**2012.04:**  
Pancreaticoduodenectomy



Ductal adenocarcinoma (pT3N0)



## Final Diagnosis

Pancreatic head cancer developing in the remnant pancreas after a  
distal pancreatectomy